gemcitabine has been researched along with Malignant Melanoma in 33 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (6.06) | 18.2507 |
2000's | 19 (57.58) | 29.6817 |
2010's | 10 (30.30) | 24.3611 |
2020's | 2 (6.06) | 2.80 |
Authors | Studies |
---|---|
Abbe, P; Benhida, R; Cavazza, E; Cerezo, M; Jaune, E; Millet, A; Plaisant, M; Rocchi, S; Ronco, C | 1 |
Garri, DD; Karamysheva, АF; Moiseeva, NI; Saakyan, SV; Tsygankov, АY | 1 |
Curiel, TJ; Deng, Y; Gupta, HB; Kancharla, A; Kari, S; Kornepati, AVR; Li, R; Osta, E; Padron, AS; Reyes, RM; Sun, X; Svatek, RS; Vadlamudi, R; Wu, B; Zhang, D | 1 |
Bonazzi, V; Daignault, SM; Fernando, M; Gabrielli, B; Haass, NK; Lanagan, C; Larsen, JE; Nazareth, D; Oo, ZY; Proctor, M; Škalamera, D; Snell, C; Stevenson, AJ; Walpole, S | 1 |
Fan, X; Ge, S; Jia, R; Song, X; Wang, J; Xu, X; Zhang, H; Zhang, Y; Zhou, Y | 1 |
Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP | 1 |
Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A | 1 |
Ishii, M; Kikuta, J; Naito, Y; Ogawa, K; Otani, K; Sakaguchi, Y; Seo, Y; Takahashi, Y | 1 |
Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K | 3 |
Cui, Z; Lansakara-P, DS; Li, X; Zhu, S | 1 |
Ding, Y; Liao, Y; Peng, RQ; Zhang, X; Zhang, XS; Zheng, LM | 1 |
Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
Clippe, C; Ligneau, B; Trillet-Lenoir, V | 1 |
Corrie, PG; Cree, IA; Haass, N; Hengge, U; Kuwert, C; Neuber, K; Pföhler, C; Reinhold, U; Tilgen, W; Ugurel, S; Zutt, M | 1 |
Bui, DT; Fruehauf, JP; Holcombe, RF; Kong, KM; Sommers, KR | 1 |
Becker, JC; Bröcker, EB; Terheyden, P | 1 |
Bechrakis, N; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, J; Thiel, E | 1 |
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
Bergman, AM; Breistøl, K; Comijn, EM; Fodstad, O; Hendriks, HR; Kuiper, CM; Myhren, F; Noordhuis, P; Peters, GJ; Sandvold, ML; Smid, K; Voorn, DA | 1 |
Benimetskaya, L; Hua, E; Khvorova, A; Lai, JC; Miller, P; Stein, CA; Wu, S; Zhang, LM | 1 |
Cree, IA; Kurbacher, CM; Neale, MH; Reinhold, U | 1 |
Bulusu, R; Corrie, PG; Cree, IA; Hartley, JA; Jonson, A; Mayer, A; Sehmbi, R; Shaw, J; Spanswick, VJ | 1 |
Baumgart, J; Bechrakis, NE; Bornfeld, N; Foerster, MH; Keilholz, U; Scheulen, ME; Schmittel, A; Strumberg, D; Thiel, E | 1 |
Blanco-Aparicio, C; Carnero, A; Fominaya, J; Leal, JF; Moneo, V; Pequeño, B; Romero, L; Velasco, J | 1 |
Bechrakis, NE; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E | 1 |
Benimetskaya, L; Miller, P; Stein, CA | 1 |
Bechrakis, NE; Foerster, MH; Keilholz, U; Martus, P; Schmidt-Hieber, M; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E | 1 |
Delorme, S; Hauschild, A; Kaatz, M; Neuber, K; Pföhler, C; Reinhold, U; Rittgen, W; Schadendorf, D; Spieth, K; Thoelke, A; Tilgen, W; Ugurel, S; Ulrich, J | 1 |
Aghajanian, C; Chi, DS; Colevas, AD; Derosa, F; Dizon, D; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
Aamdal, S; Eppelbaum, R; Franklin, H; Sessa, C; Smyth, JF; Sulkes, A; Ten Bokkel Huinink, W; Vermorken, J; Wanders, J; Wolff, I | 1 |
Cree, IA; Foss, AJ; Hungerford, JL; Kurbacher, CM; Myatt, N; Neale, MH; Plowman, PN | 1 |
1 review(s) available for gemcitabine and Malignant Melanoma
Article | Year |
---|---|
[Role of gemcitabine in the treatment of other malignant tumors].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Melanoma; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome; Uterine Cervical Neoplasms | 2002 |
14 trial(s) available for gemcitabine and Malignant Melanoma
Article | Year |
---|---|
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Cohort Studies; Cytarabine; Deoxycytidine; Female; Gemcitabine; Histones; Humans; Infusions, Intravenous; K562 Cells; Male; Melanoma; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Sarcoma; Time Factors | 2015 |
A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2012 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pilot Projects; Survival Analysis; Uveal Neoplasms | 2003 |
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome; Uveal Neoplasms | 2004 |
A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Treatment Outcome; Uveal Neoplasms | 2004 |
Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comet Assay; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Uveal Neoplasms | 2005 |
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leukopenia; Male; Melanoma; Middle Aged; Survival Analysis; Thrombocytopenia; Uveal Neoplasms | 2005 |
A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Uveal Neoplasms | 2005 |
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Uveal Neoplasms | 2006 |
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Kidney Neoplasms; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Uterine Neoplasms; Water-Electrolyte Imbalance | 2007 |
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Recurrence; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Neutropenia; Stomach Neoplasms | 1994 |
18 other study(ies) available for gemcitabine and Malignant Melanoma
Article | Year |
---|---|
Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Mice; Pancreatic Neoplasms; Structure-Activity Relationship; Thiazoles | 2016 |
Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo.
Topics: Adult; Aged; Antineoplastic Agents; Benzeneacetamides; Busulfan; Cell Proliferation; Cell Survival; Choroid Neoplasms; Deoxycytidine; Diterpenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Phenylacetates; Primary Cell Culture; Retinyl Esters; Tumor Cells, Cultured; Uveal Neoplasms; Valproic Acid | 2020 |
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Autophagy; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Sirolimus; Urinary Bladder Neoplasms | 2021 |
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Hydroxyurea; Lung Neoplasms; Melanoma; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors | 2019 |
The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Uveal Neoplasms | 2014 |
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Phthalimides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
Cell-cycle-controlled radiation therapy was effective for treating a murine malignant melanoma cell line in vitro and in vivo.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Epithelial Cells; Gemcitabine; Humans; Melanocytes; Melanoma; Mice; Radiation-Sensitizing Agents; Treatment Outcome | 2016 |
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Lysosomes; Melanoma; Mice; Mice, Inbred C57BL; Micelles; Polyethylene Glycols; Prodrugs; Stearic Acids | 2012 |
Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Radiography; Skin Neoplasms; Stevens-Johnson Syndrome | 2003 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Carbon; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; DNA; DNA Damage; Fatty Acids; Gemcitabine; Humans; Inhibitory Concentration 50; Leukemia; Melanoma; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Nucleoside Deaminases; Phosphorylation; Rats; Time Factors | 2004 |
Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Taxoids; Thapsigargin; Thionucleotides; Tumor Cells, Cultured | 2004 |
Treosulfan and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Gemcitabine; Humans; Melanoma; Reproducibility of Results; Uveal Neoplasms | 2005 |
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.
Topics: bcl-2-Associated X Protein; bcl-X Protein; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Deoxycytidine; DNA-Binding Proteins; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression; Genes, Tumor Suppressor; Humans; Inhibitory Concentration 50; Leiomyosarcoma; Melanoma; Mitochondria; Morpholines; Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Guanine; Humans; Melanoma; Oligonucleotides, Antisense; Thionucleotides | 2005 |
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Uveal Neoplasms | 2008 |
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Melanoma; Paclitaxel; Tumor Stem Cell Assay | 1999 |